Company / Free Cash Flow
Adaptimmune Therapeutics PLC Free Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$74.1M
FY2024
5-year range
-$171.3M / $2.2M
FY2020-FY2024
Trend
+49.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 9 years, ranging from -$171M in FY2022 to $2M in FY2021.
Based on SEC 10-K filings.
-$74M in FY2024.
Improved from -$171M to -$74M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, free cash flow increased 49.1% year-over-year.
- Peak free cash flow was recorded in FY2021.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$74.1M | +49.1% |
| FY2023 | -$145.6M | +15.0% |
| FY2022 | -$171.3M | -8047.3% |
| FY2021 | $2.2M | +103.9% |
| FY2020 | -$55.9M | +51.0% |
| FY2019 | -$114.1M | -5.4% |
| FY2018 | -$108.3M | -37.2% |
| FY2017 | -$79.0M | -32.3% |
| FY2016 | -$59.7M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026